Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

Jan. 10, 2002

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

Jan. 10, 2002

Antisense oligonucleotide targeting Ki-ras as an approach to colorectal cancer

Jan. 10, 2002

Endothelial cell-specific inhibition of protein synthesis demonstrated for tumstatin

Jan. 10, 2002

Prescient NeuroPharma licenses anhydrovinblastine to Access Oncology

Jan. 10, 2002

Study protocol changes following early positive results for Gleevec in CML

Jan. 9, 2002

Idec's BLA for Zevalin radioimmunotherapy approvable according to FDA

Jan. 9, 2002

Millennium initiates phase I clinical program of MLN-341 in combination with Taxotere

Jan. 9, 2002

Antitumor activity demonstrated for new series of caprolactam carbonates

Jan. 9, 2002

Study demonstrates safety, preliminary efficacy of squalamine as 120-hour infusion

Jan. 9, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...